Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing

Antimicrob Agents Chemother. 2007 Oct;51(10):3760-2. doi: 10.1128/AAC.00488-07. Epub 2007 Aug 6.

Abstract

Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algorithms
  • Amphotericin B / pharmacokinetics
  • Amphotericin B / therapeutic use*
  • Antifungal Agents / administration & dosage*
  • Antifungal Agents / pharmacokinetics
  • Antifungal Agents / therapeutic use*
  • Area Under Curve
  • Candidiasis / drug therapy*
  • Candidiasis / microbiology
  • Child
  • Drug Interactions
  • Flucytosine / administration & dosage*
  • Flucytosine / pharmacokinetics
  • Flucytosine / therapeutic use*
  • Humans
  • Models, Statistical
  • Monte Carlo Method

Substances

  • Antifungal Agents
  • Amphotericin B
  • Flucytosine